New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:28 EDTHSH, JKS, FRO, ARO, SDRL, BCRX, PFE, AZN, PF, PPC, SPLSOn The Fly: Pre-market Movers
HIGHER: Pilgrim's Pride (PPC), up 5% after proposing to acquire Hillshire Brands (HSH) for $45.00 per share cash. Hillshire up 21% following the news, while Pinnacle Foods (PF), which has agreed to be acquired by Hillshire, is down 6.4%... BioCryst (BCRX), up 19% after announcing "positive" results from OPuS-1, a trial of BCX4161... Seadrill (SDRL), up 2.6% after signing investment and cooperation pact with Rosneft and North Atlantic... Aeropostale (ARO), up 11% after $150M financing transaction with Sycamore. LOWER: AstraZeneca (AZN), down 1.7% after downgraded at Societe Generale following Pfizer (PFE) confirming it won't bid for AstraZeneca after rejection of proposal. Pfizer shares are up 1% after the news... Staples (SPLS), down 1% after downgraded at Goldman... Frontline (FRO), down 7.4% after saying it sees weaker Q2 operational results... JinkoSolar (JKS), down 7.8% after reporting lower than expected Q1 earnings results.
News For HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS From The Last 14 Days
Check below for free stories on HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
07:14 EDTFROFrontline announces termination of charter-in contracts of VLCCs
Frontline (FRO) has agreed with Ship Finance International (SFL) to terminate the long term charter parties for the 1999 built VLCCs Front Opalia, Front Comanche and Front Commerce and Ship Finance has simultaneously sold the vessels to unrelated third parties. The charter parties are expected to terminate in Q4. The decision to terminate the long term charter parties was taken in view of the required investment to take the vessels through the 15 year special survey. Frontline has agreed an aggregate compensation payment to Ship Finance of approximately $58.8M for the early termination of the charter parties, of which approximately $10.5M will be paid upon termination and the balance will be recorded as notes payable, with similar amortisation profiles to the current lease obligations, with reduced rates until December 2015 and full rates from 2016. As of June 30, the company has capital lease obligations to Ship Finance of $101.5M and $608.3M for these three vessels and the remaining 12 VLCCs and five Suezmax tankers, respectively.
July 22, 2014
16:18 EDTPFEPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 18, 2014
12:48 EDTJKSSolar stocks rise after successful IPO in space
Shares of solar energy companies are rising after a solar energy company's subsidiary surged on its first day of trading. WHAT'S NEW: The shares of SunEdison (SUNE) subsidiary TerraForm (TERP) are surging 36% in early afternoon trading. TerraForm Power opened at $33.26 and was trading near $34 per share at midday, after its initial public offering priced at $25 per share. TerraForm was formed to own and operate assets that generate clean power and the company plans to pay dividends. In a note to investors yesterday, Josh Baribeau, an analyst at Canaccord Genuity, wrote that TerraForm is a Yieldco. Subsidiaries of energy companies that own power plants and projects, Yieldcos typically trade on stock exchanges. Noting that TerraForm's IPO had priced at the high end of its expected range yesterday and was well oversubscribed, Baribeau wrote that this outcome reflects the strong demand for Yieldcos among investors. The Yieldcos provide investors with yield which is in high demand in today's low interest rate environment, the analyst stated. Additionally, as a result of the strong demand for Yieldcos' stocks, they provide their parent companies with "cheap and abundant capital," the analyst stated. SunEdison and TerraForm will grow their combined cash available for distributions at a faster rate than their target of 15% over the next three years, helping SunEdison's stock rise, the analyst stated. He kept a $30 price target and Buy rating on SunEdison. WHAT'S NOTABLE: A number of solar energy companies that own solar projects could form Yieldcos, research firm Trefis wrote in a Forbes column last month. Like Canaccord's Baribeau, Trefis believes that Yieldcos provide their parent companies with a cheap source of funding. Yieldcos also distribute most of their cash through dividends, Trefis stated. The firm named First Solar (FSLR) and SunPower (SPWR) as companies that could launch their own Yieldcos. PRICE ACTION: In early afternoon trading, Terraform jumped 36% to $34 and SunEdison was down 1% to $22.76. Meanwhile, First Solar rose 1.4% to $62.29, SunPower climbed 2.7% to $38.71, JinkoSolar gained 2.8% to $26.75, and Canadian Solar (CSIQ) advanced 3% to $28.71.
July 17, 2014
08:08 EDTPFEBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
July 16, 2014
17:23 EDTHSHTyson Foods commences tender offer for Hillshire Brands for $63 per share cash
Tyson Foods (TSN) announced that it has commenced a cash tender offer for all outstanding shares of common stock of Hillshire Brands (HSH) at a price of $63.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated July 1, among the two companies and HMB Holdings, a wholly owned subsidiary of Tyson Foods. The tender offer period will expire at 12:00 midnight at the end of the day on August 12, unless the offer is extended. Tyson Foods has filed a tender offer statement on Schedule TO with the United States SEC. HMB Holdings is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer. Hillshire Brands has also filed a Solicitation/Recommendation Statement with the SEC, which includes the recommendation of the Hillshire board of directors that Hillshire Brands stockholders tender their shares in the tender offer. Following successful completion of the tender offer, any shares not acquired in the tender offer will be acquired in a second-step merger at the same $63 per share cash price.
10:36 EDTAZN, PFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZN, PFETreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:12 EDTJKSJinkoSolar signs RMB1B strategic financing agreement with China Minsheng Bank
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
July 15, 2014
10:48 EDTHSHOptions with increasing implied volatility: GLUU KORS RVBD HSH
10:00 EDTPFOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTSDRLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:41 EDTSDRLSeadrill upgraded to Market Perform from Underperform at BMO Capital
Subscribe for More Information
06:32 EDTSPLSStaples, USPS cease in-store mini-post office program, Reuters says
After several protests outside of its stores, Staples said it is set to end a pilot program with the U.S. Postal Service to set up mini-post offices in the firm's retail locations, according to Reuters, citing comments from spokeswomen representing Staples and the USPS. Reference Link
05:51 EDTPFPinnacle Foods reinstated with a Neutral at Goldman
Subscribe for More Information
July 13, 2014
15:54 EDTSPLSGameStop, TJX, Staples, three other retailers look cheap, Barron's says
Subscribe for More Information
July 10, 2014
11:18 EDTAROZumiez rallies after raising second quarter outlook
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use